Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer
Lap-NET1 clinical trial Study design and participants Lap-NET1 is a multicentric, prospective, single-arm phase 1b trial. This study included a safety lead-in phase to confirm the recommended dose of NP137 in combination with mFOLFIRINOX (ClinicalTrials.gov identifier: NCT05546853). Patients were enrolled and treated between March 2023 and June 2024 at nine sites in France. Eligible patients…